Modified AAV9 Capsid for Targeted CNS Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adeno-associated virus (AAV) vectors used for gene therapy in central nervous system (CNS) disorders face challenges such as toxicity and biodistribution limitations, leading to safety and dosing issues.
Innovation Solution
Development of recombinant adeno-associated virus (rAAV) viral particles with a modified AAV9 capsid and an expression cassette encoding a disorder-related polypeptide or RNAi molecule, designed for administration into the cerebrospinal fluid to achieve targeted gene expression in the CNS with minimal off-target expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional AAV vectors are used for CNS gene therapy, then gene delivery capability is achieved, but toxicity and biodistribution limitations occur
Solution Approach 1:
The patent modifies the AAV9 capsid with specific amino acid mutations (e.g., E647G, E647R, or other capsid variants) to create a localized quality change in the viral particle's tissue tropism. This modification enables the vector to preferentially transduce CNS tissues while reducing off-target expression in peripheral tissues, thereby resolving the contradiction between achieving CNS gene delivery and minimizing toxicity through improved biodistribution specificity.
2Reliability
If conventional AAV vectors are used for CNS gene therapy, then therapeutic expression is achieved, but off-target expression in peripheral tissues occurs
Solution Approach 1:
The capsid modification introduces localized quality changes that differentiate the vector's affinity for CNS versus peripheral tissues. The mutated capsid proteins interact selectively with CNS-specific cell surface receptors, enabling high-level therapeutic expression in the CNS while minimizing off-target expression in peripheral nervous system tissues, thus resolving the efficacy-safety contradiction.
3Reliability
If high dose AAV vectors are administered, then therapeutic expression levels are achieved, but safety issues arise
Solution Approach 1:
The patent changes the parameter of capsid amino acid sequence to alter the vector's biological properties. By introducing specific mutations in the capsid protein, the vector achieves enhanced CNS transduction efficiency at lower doses, thereby achieving therapeutic expression levels without the safety issues associated with high-dose administration of conventional vectors.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enables high levels of expression of therapeutic molecules in the CNS while minimizing expression in peripheral nervous system tissues, potentially addressing the safety and efficacy limitations of current AAV vector therapies.
Implementation Method 1
a modified AAV9 capsid capable of transducing the cells of the central nervous system (CNS)
Data Source
AI summary
Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a disorder-related polypeptide. Also provided are methods to treat various neurodegenerative disorders. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions and kits for expressing a disorder-related polypeptide in an individual in need thereof.